Board Change

RNS Number : 5418N

Ergomed plc

25 September 2019

 

PRESS RELEASE

Board Change

Guildford, UK - 25 September 2019: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the global pharmaceutical industry, today announces that Peter George will step down from the Board with immediate effect to focus on his other business activities, in particular Benchmark Holdings plc where he was recently appointed Executive Chairman.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Peter has been an integral part of the Ergomed Board for over five years, in which time he has held the roles of Non-Executive Chairman, Senior Independent Director and Non-Executive Director. During this period, he has made a very significant contribution to the Company's strategy, growth and success. On behalf of the Board, I would like to thank Peter for his energy, wise counsel and commitment to Ergomed and wish him well in all his future endeavours."

Peter George said: "It has been a privilege to play a part in the successful growth of Ergomed and I am pleased to be leaving with the Company in very good health both financially and operationally. With its highly differentiated offering, which combines specialist CRO services and pharmacovigilance, and an outstanding management team and Board compiled of industry experts, Ergomed is well positioned to fulfil its undoubted potential as a leading global mid-tier CRO."

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

 

END

 

 

BOASELESLFUSEFU